Abstract
A series of fourteen (14) N-nitrophenyl-N'-(alkyl/aryl)urea and symmetrical 1,3-disubstituted urea derivatives were synthesized and evaluated for their antidepressant activity in mice. Among them, N-(4-nitrophenyl)-N'-(1'-phenylethyl)urea (1), demonstrated profound antidepressant property as reflected by significant reduction in the immobility time (89.83%), whereas compounds 2-6 showed activity values between 36 to 59% which were also larger than the standard phenelzine. Compounds 7-9 were less effective in reducing the immobility period of mice 26.20 to 31.01%). This variable magnitude of antidepressant activity appears to be related to the position of the nitro group to the parent molecules 1, 2, and 8. Compound 1 with the nitro group at para position showed to be the most effective antidepressant. However, the activity declined, if the nitro is attached to ortho and meta positions.
Keywords: Amines, Antidepressant, Disubstituted urea derivatives, Isocyanate, Symmetrical urea, Tail suspension test (TST), carbamates, lipoproteinelevating, cholinergic agents
Medicinal Chemistry
Title:Substituted Urea Derivatives: A Potent Class of Antidepressant Agents
Volume: 8 Issue: 3
Author(s): Shahnaz Perveen, Sana Mustafa, Muhammad A. Khan, Ahsana Dar, Khalid M. Khan and Wolfgang Voelter
Affiliation:
Keywords: Amines, Antidepressant, Disubstituted urea derivatives, Isocyanate, Symmetrical urea, Tail suspension test (TST), carbamates, lipoproteinelevating, cholinergic agents
Abstract: A series of fourteen (14) N-nitrophenyl-N'-(alkyl/aryl)urea and symmetrical 1,3-disubstituted urea derivatives were synthesized and evaluated for their antidepressant activity in mice. Among them, N-(4-nitrophenyl)-N'-(1'-phenylethyl)urea (1), demonstrated profound antidepressant property as reflected by significant reduction in the immobility time (89.83%), whereas compounds 2-6 showed activity values between 36 to 59% which were also larger than the standard phenelzine. Compounds 7-9 were less effective in reducing the immobility period of mice 26.20 to 31.01%). This variable magnitude of antidepressant activity appears to be related to the position of the nitro group to the parent molecules 1, 2, and 8. Compound 1 with the nitro group at para position showed to be the most effective antidepressant. However, the activity declined, if the nitro is attached to ortho and meta positions.
Export Options
About this article
Cite this article as:
Perveen Shahnaz, Mustafa Sana, A. Khan Muhammad, Dar Ahsana, M. Khan Khalid and Voelter Wolfgang, Substituted Urea Derivatives: A Potent Class of Antidepressant Agents, Medicinal Chemistry 2012; 8 (3) . https://dx.doi.org/10.2174/157340612800786615
DOI https://dx.doi.org/10.2174/157340612800786615 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress and Decreased Mitochondrial Superoxide Dismutase 2 and Peroxiredoxins 1 and 4 Based Mechanism of Concurrent Activation of AMPK and mTOR in Alzheimer’s Disease
Current Alzheimer Research Meet Our Regional Editor
CNS & Neurological Disorders - Drug Targets Intranasal Insulin Prevents Anesthesia-induced Cognitive Impairments in Aged Mice
Current Alzheimer Research Homocysteine, Intracellular Signaling and Thrombotic Disorders
Current Medicinal Chemistry The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies
Current Drug Targets Neural Stem Cells: From Neurobiology to Clinical Applications
Current Pharmaceutical Biotechnology Preface
Central Nervous System Agents in Medicinal Chemistry Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets Neuropeptide Y as an Endogenous Antiepileptic, Neuroprotective and Pro-Neurogenic Peptide
Recent Patents on CNS Drug Discovery (Discontinued) Amelioration of Myocardial Ischemic Reperfusion Injury with Calendula Officinalis
Current Pharmaceutical Biotechnology Nanostructured Lipid Carriers (NLCs) for Drug Delivery: Role of Liquid Lipid (Oil)
Current Drug Delivery Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Drug Therapy for Patients with Eating Disorders
Current Drug Targets - CNS & Neurological Disorders Current Therapy of Drugs in Amyotrophic Lateral Sclerosis
Current Neuropharmacology Coronary Risk Factors in the Elderly: Their Interactions and Treatment
Current Pharmaceutical Design Metabolomics and Its Practical Value in Pharmaceutical Industry
Current Drug Metabolism A MicroRNA-BDNF Negative Feedback Signaling Loop in Brain: Implications for Alzheimer’s Disease
MicroRNA Recent Developments in Mass Spectrometry Analysis of Phosphoproteomes
Current Proteomics A Current Update on the Use of Alpha Lipoic Acid in the Management of Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Medical Management and Risk Reduction of the Cardiovascular Effects of Underwater Diving
Current Vascular Pharmacology